Dianosic Closes 1.5 Million Euros Funding Round

Dianosic, a Strasbourg-based start-up specializing in solutions for ear, nose and throat (ENT) conditions, has announced a first round of more than 1.5 million euros ($1.63 million) in capital and non-dilutive funding from PAF Kapital, a group of business angels, Bpifrance Alsace, the Grand Est Region and two banks, Caisse d’Epargne Grand-Est Europe and Banque Populaire Rives de Paris. The money will be used to support the European launch of its CE Marked intranasal bleeding treatment device.
 
This is the first round of funding for Dianosic since its creation in July 2017 by Marc Augustin, Philippe Bastide and Pr Christian Debry, head of the ENT & Head and Neck Surgery Department of the Strasbourg University Hospital.
 
The company won the i-Lab contest in 2019, organized by the French Ministry of Higher Education, Research and Innovation, in partnership with Bpifrance.
 
Dianosic offers disruptive answers to medical needs for pathologies of the nasal cavity that are currently insufficiently covered. Its first device is the asymmetrical intranasal balloon, CAVI-T, which stops spontaneous or postoperative bleeding (hemostasis) with low pressure compression, adapting to the unique anatomy of the nasal cavity. It is covered by a patent valid for France and it will soon be covered in Europe, the United States, Japan, and China.
 
“For doctors and surgeons, in their daily practice, this device will considerably ease the care of those patients who can benefit from this innovative product,” said Pr. Christian Debry.
 
With its second medical device, the Active Resorbable Intranasal Scaffold (ARIS), currently under development, Dianosic aims to revolutionize the management of chronic sinusitis, which affects 10 percent of the general population. Resorbable and minimally invasive, the ARIS device delivers a steroid in a targeted manner to patients over a long-term period (12 months) without needing prior surgery, unlike current solutions.
 
“This round of financing will allow us to accelerate the launch of our first product, CAVI-T, dedicated to the treatment of intranasal bleeding (epistaxis), and to strengthen our portfolio with the ARIS solution, a major breakthrough in the management of chronic sinusitis,” said Marc Augustin, president of Dianosic. “Our goal is to position Dianosic as a European leader in the treatment of nasal cavity pathologies.”
 
“With the ARIS device, Dianosic’s ambition is to address the limitations observed with current treatments for chronic sinusitis. In this context, our solution will enable patients not responding to first-line drug treatments to benefit from an effective, long-term treatment whilst preserving quality of life for those living with this debilitating disease. The ARIS device will also provide hospitals with an adequate outpatient response to a pathology that is very costly for the community,” said Philippe Bastide, CEO of Dianosic.
 
“PAF Kapital is delighted to support Dianosic in the marketing and development of its innovative solutions for ENT pathologies,” said Jean-François Auffret, PAF Kapital. “We believe in the technology developed by the company, but also in its team and its know-how.”